Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days for Prevention of Venous Thromboembolism in Patients With Curative Abdominal Cancer Surgery. Physical Prophylaxis Only Arm [Intermittent Pneumatic Compression (IPC)] Will be Used as an Indicator of Event Rates

Trial Profile

Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days for Prevention of Venous Thromboembolism in Patients With Curative Abdominal Cancer Surgery. Physical Prophylaxis Only Arm [Intermittent Pneumatic Compression (IPC)] Will be Used as an Indicator of Event Rates

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2010

At a glance

  • Drugs Enoxaparin sodium (Primary)
  • Indications Thromboembolism
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Mar 2010 Results published in Thrombosis Research.
    • 11 Jul 2009 Results presented at the 22nd Congress of the International Society on Thrombosis and Haemostasis.
    • 19 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top